ClinicalTrials.gg
RecruitingNCT07014917ESR-23-22182Updated Jan 6, 2026

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

A Phase 2 interventional study of Venetoclax and Acalabrutinib in Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and CLL Variant, sponsored by Zulfa Omer. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Zulfa Omer · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
39th of 69
62 · median 72
Started
2025
with 4 others
Phase 2
41 of 69
16 open now
Primary completion
2028-06
later than 31 of 41 live
Registered
62nd of 69
by date

Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 39th largest by planned enrollment, is one of 5 that started in 2025, is one of 41 in phase 2, reaches primary completion later than 31 of the 41 other live ones, and was the 62nd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This is a randomized Phase II study of intermittent versus continuous venetoclax therapy with Acalabrutinib in previously untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Read the detailed description

This study is a two-arm, open label, Phase II multicenter clinical trial designed to evaluate the intermittent and continuous venetoclax + acalabrutinib in 2 arms in previously untreated CLL/SLL.

Phase II trial will be in two separate arms using Simon's 2-stage design for each. Subjects will be randomized with 2:1 ratio into Arm A which will receive intermittent venetoclax (7days administration per cycle) + acalabrutinib and Arm B which will receive continuous venetoclax (28 days administrations per cycle) + acalabrutinib.

With this trial we are seeking to establish efficacy of the combination therapy in both treatment models (intermittent and continuous venetoclax) and to acquire pilot data characterizing the effectiveness of the combination in increasing the depth of response as reflected in the rate of uMRD CR. We will reject the null hypothesis for each arm separately if CR at Cycle 12 obtained in 8 patients in Arm A and 5 patients in Arm B and move forward for a larger phase 3 study.

A continuous toxicity monitoring model to monitor adverse events will be used. This model has been used successfully with phase II trials designed with the Simon 2-Stage. This methodology will allow us to monitor the cumulative number of toxic events after each patient is treated and hence to stop the study if the drug toxicities exceeded the prespecified toxicity boundary.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • CLL Variant

Keywords

  • Venetoclax
  • Acalabrutinib
  • CLL
  • SLL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) as defined by the IWCLL including variation of flow cytometry, provided cytogenetic or mutational data are supportive of CLL/SLL diagnosis that requires therapy by one IWCLL criteria; and, must be previously untreated CLL/SLL.

    a. Note: Variation in flow cytometry is defined as patients who have atypical immunophenotyping for CLL (CD5 negative, CD23 negative or surface expression of CD79b that is bright) but clinically behave like CLL (leukocytosis, lymphadenopathy and splenomegaly) and have the FISH/Cytogenetics translocations (del 13q, trisomy 12, Del11q) or genomic features (XPO1, NOTCH1, SF3B1, FBXW7, MYD88, BIRC3, TRAF3, NFKBIE, SAMHD1, POT1, HIST1H1E, CHD2, ZMYM3, EGR2 and others) that are suggestive of CLL

  2. Men and Women ≥18 years of age.
  3. (ECOG) performance status of 0, 1, or 2 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
  4. Subjects must have adequate organ and marrow function as defined below:

    1. ≥1,000/mcL, unless if neutropenia is due to extensive underlying CLL bone marrow disease then threshold will be ANC ≥500/mcL unless WBC is > to 50 x 109/L. If WBC is > to 50 x 109/L there will be no lower threshold of ANC. Use of for disease control is allowed.
    2. Platelets ≥30,000/mcL unless thrombocytopenia is due to extensive underlying CLL bone marrow disease platelets threshold will be ≥ 10, 000/mcl. Use of steroids for disease control is allowed.
    3. Total ≤1.5 x unless directly attributable to Gilbert's syndrome
    4. and ALT ≤3 × ULN
    5. (Cockcroft) ≥30 mL/min/1.73 m2 • CrCl by Cockcroft and Gault method: CrCl (mL/min) = (140 - age [years]) × weight (kg) × (F)a (72 × serum creatinine mg/dL a where F = 0.85 for females and F = 1 for males ≥ 30 mL/minute
  5. Female subjects who are sexually active and can bear children must agree to use highly effective forms of while on the study and for 2 days after the last dose of acalabrutinib.
  6. Male subjects who are sexually active must agree to use highly effective forms of contraception with the addition of a barrier method (condom) during the study.
  7. Men must agree to refrain from sperm donation during the study.
  8. Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing tablets without difficulty.
  9. Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information (in accordance with national and local patient privacy regulations).

Exclusion criteria

Exclusion Criteria:

  1. Evidence of any active concurrent disease (such as severe or uncontrolled systemic diseases that, in the investigator's opinion, make it undesirable for the patient to participate in the study or that would jeopardize compliance with the protocol.
  2. Patients with active Richter's transformation.
  3. History of or ongoing confirmed central nervous system (CNS) lymphoma.
  4. Received any drug within 30 days or 5 half-lives (whichever is shorter) before first dose of study drug.
  5. Major surgical procedure within 30 days before the first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug.
  6. History of prior that could affect compliance with the protocol or interpretation of results in the opinion of the investigator, except for the following:

    1. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin, carcinoma in situ of the cervix, breast or prostate at any time prior to study that are adequately treated. Patients with cancer not requiring therapy (ex: early prostate cancer under observation, should be discussed with Study PI).
    2. Continuation of maintenance therapy in patients with adequately treated malignancy
    3. Other cancers not specified above that have been curatively treated by surgery and/or radiation therapy and/or chemotherapy from which subject is disease-free for ≥3 years without further treatment
  7. Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification at Screening.

    a. Note: Subjects with controlled, asymptomatic atrial fibrillation are allowed to enroll on study.

  8. Patients with a condition that would preclude adequate absorption, distribution, metabolism, or excretion of study treatment. For example, nausea and vomiting, inability to swallow the formulated product, or malabsorption syndrome; chronic gastrointestinal disease gastric restrictions, or bariatric surgery such as gastric bypass; partial or complete bowel obstruction, or previous significant bowel resection.
  9. Received a within 28 days of first dose of study drug.
  10. Uncontrolled infection.
  11. History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML).
  12. Any active uncontrolled significant infection (e.g., bacterial, viral or fungal), including subjects with positive cytomegalovirus [CMV] DNA polymerase chain reaction [PCR]).
  13. Serologic status reflecting active or C infection.

    1. Note: Subjects who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative PCR result before randomization and must be willing to undergo DNA PCR testing during the study. Those who are HbsAg-positive or hepatitis B PCR positive will be excluded.
    2. Subjects who are antibody positive will need to have a negative PCR result before randomization. Those who are hepatitis C PCR positive will be excluded.
  14. History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.
  15. Uncontrolled bleeding diathesis (e.g., hemophilia, von Willebrand disease).
  16. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists.

    a. Note: DOAC or LMWH are not exclusionary.

  17. Requires treatment with a strong cytochrome P450 3A () inhibitor or inducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited. Patient who have started those inhibitor or inducers with known dose outside above timeline will follow dose reduction schedule provided in the protocol and package insert of venetoclax and acalabrutinib.
  18. Breastfeeding or pregnant.
  19. Concurrent participation in another therapeutic clinical trial.
  20. Current life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the subject's safety or put the study at risk.
  21. Requires treatment with P-glycoprotein (P-gp) inhibitor during venetoclax initiating and dose escalation phase.

    Note: After initiation of the study drug(s) once a stable dose is reached if P-gp inhibitors are required then these P-gp inhibitors will be allowed per the reduction tables within the protocol or per the study drug(s) package insert/IB.

  22. Patients who are unable to receive Prevnar vaccination.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Arm A: intermittent venetoclax

    intermittent venetoclax (7days administration per cycle) + acalabrutinib

    Drug: Venetoclax · Drug: Acalabrutinib

  • Experimental
    Arm B: continuous venetoclax

    continuous venetoclax (28 days administrations per cycle) + acalabrutinib

    Drug: Venetoclax · Drug: Acalabrutinib

Interventions

  • intermittent venetoclax (7days administration per cycle) + acalabrutinib

  • intermittent venetoclax (7days administration per cycle) + acalabrutinib

  • continuous venetoclax (28 days administrations per cycle) + acalabrutinib

  • continuous venetoclax (28 days administrations per cycle) + acalabrutinib

06

What researchers measure

Primary outcomes

  1. Complete Remission defined by the IWCLL 2018 criteria

    Complete Remission (CR) as defined by the IWCLL 2018 criteria after 12 cycles of treatment with acalabrutinib in combination with intermittent or continuous venetoclax in patients with untreated CLL/SLL.

    Time frame: Post 12 cycles of treatment (each cycle is 28 days)

Secondary outcomes

  1. Circulating numbers of NK cells measured by flow cytometry

    Circulating numbers of NK cells using flow cytometry in both treatment arms at pretreatment, C1, C4, C6, C9, C12 and 3 months after completion of treatment.

    Time frame: Pretreatment, Cycle1, Cycle4, Cycle6, Cycle9, Cycle12 and 3 months after completion of treatment (each cycle is 28 days)

  2. Circulating numbers of T cells measured by flow cytometry

    Circulating numbers of T cells using flow cytometry in both treatment arms at pretreatment, C1, C4, C6, C9, C12 and 3 months after completion of treatment.

    Time frame: Pretreatment, Cycle1, Cycle4, Cycle6, Cycle9, Cycle12 and 3 months after completion of treatment (each cycle is 28 days)

  3. Overall Survival -defined as time from study randomization to death or last follow up

    Overall Survival (OS) defined as time from study randomization to death or last follow up

    Time frame: From date of patient baseline visit to death or last follow up (up to 5 years post treatment).

  4. Progression Free Survival (PFS) defined as the time from study randomization to disease progression, death, or last follow up after treatment

    Progression Free Survival (PFS) defined as the time from study randomization to disease progression, death, or last follow up after treatment with acalabrutinib in combination with intermittent or continuous venetoclax in patients with untreated CLL/SLL.

    Time frame: From date of patient baseline visit to death or last follow up (up to 5 years post treatment).

  5. uMRD Complete Remission (CR) defined by negative luekemia cell to 10-6 using NGS Clonoseq

    The rate of uMRD Complete Remission (CR) defined by negative luekemia cell to 10-6 using NGS Clonoseq from bone marrow and peripheral blood samples after 12 cycles of treatment with acalabrutinib in combination with intermittent or continuous venetoclax in patients with untreated CLL/SLL.

    Time frame: Post 12 cycles of treatment (each cycle is 28 days)

  6. Rate of Tumor lysis syndrome

    Tumor lysis syndrome (TLS) after outpatient rapid dose escalation of venetoclax in both treatment arms.

    Time frame: Cycle 4 of therapy (each cycle is 28 days); post intervention point of outpatient rapid dose escalation of venetoclax

  7. Response to vaccination measured by Levels of antibody titer

    Levels of antibody titer in response to vaccination with Prevnar 20 at 3 months (+/- 1 month) from completion of all treatment.

    Time frame: 3 months (+/- 1 month) from completion of all treatment.

Other outcomes

  1. BAX clonal hematopoiesis using NGS

    BAX clonal hematopoiesis using NGS at Cycle 12, 3 and 5 years post treatment

    Time frame: Cycle 12, 3 and 5 years post treatment (each cycle is 28 days)

  2. Development of Secondary cancer

    Secondary cancer development at 3- and 5-years post treatment

    Time frame: 3- and 5-years post treatment

  3. Quality of life measured by EORTC QLQ-CLL17 survey

    Quality of life measures in the intermittent and continuous venetoclax treatment groups at baseline (prior to first dose), cycle 1, cycle 6, cycle 9 and end of cycle 12.

    Time frame: Baseline (prior to first dose), cycle 1, cycle 6, cycle 9 and end of cycle 12 (each cycle is 28 days)

  4. Mechanism of toxicity

    Mechanism of toxicity to this combination at baseline (pre-treatment) and at C1, 4, 6, 9, and C12

    Time frame: Baseline (pre-treatment) and at cycle 1,cycle 4, cycle 6, cycle 9, and cycle 12 (each cycle is 28 days)

  5. Mechanism of resistance

    Mechanism of resistance to this combination at baseline (pre-treatment) and at Cycle1, Cycle4, Cycle6, Cycle9, and Cycle12 (each cycle is 28 days)

    Time frame: baseline (pre-treatment) and at Cycle1, Cycle4, Cycle6, Cycle9, and Cycle12 (each cycle is 28 days)

  6. BTK mutations development rate

    BTK mutations development rate every 6 months from year 2 of completion of therapy till year 5.

    Time frame: every 6 months from year 2 of completion of therapy until year 5.

  7. Disease relapse rate

    Disease relapse rate every 6 months from year 2 of completion of therapy till year 5.

    Time frame: every 6 months from year 2 of completion of therapy untilyear 5.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2028, 30 months after the start.

Of 207 non-industry phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's planned 30 months is below that.

Counting every sponsor, half of 248 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2025
First posted
Jun 11, 2025
StartActual
Dec 5, 2025
Primary completionEst.
Jun 5, 2028
CompletionEst.
Jun 5, 2032
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07014917
Lead sponsor
Zulfa Omer
Responsible party
Zulfa Omer (Principal Investigator, University of Cincinnati) — Sponsor-investigator
First posted
Jun 11, 2025
Start date
Dec 5, 2025
Primary completion
Jun 5, 2028 (estimated)
Completion
Jun 5, 2032 (estimated)
Last update
Jan 6, 2026

Study contacts

UCCC Clinical Trials Office
Contact
cancer@uchealth.com
513-584-7698
Zulfa Omer, MD
Contact
cancer@uchealth.com
Zulfa Omer
principal investigator · University of Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Acalabrutinib

Start the discussion